Biohit Oyj Press Release
8 December 2025 at 10:30 a.m. EEST
New Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy
Major Cost Savings Possible
A newly published clinical study confirms that when GastroPanel® results are normal, upper endoscopy (gastroscopy) is typically unnecessary.
This is a significant breakthrough for global healthcare systems struggling with tight budgets, rising costs, long waiting lists, and limited specialist capacity.
Why this matters
The research, known as the Kappa-Study, was conducted at Oulu University Hospital and published in Anticancer Research (2025). It shows a very high agreement between GastroPanel® results and biopsy histology, confirming the test as a reliable non-invasive triage tool for patients with upper-abdominal symptoms.
Biohit CEO Jussi Hahtela:
“The results speak clearly: if GastroPanel® is normal, gastroscopy is almost never needed. This is a turning point that could save huge costs and significantly shorten waiting lists.”
GastroPanel® is currently gaining international attention as a scalable solution to improve efficiency in gastric diagnostics.
For further information, please contact:
Jussi Hahtela, CEO, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohit.fi
Biohit in brief
Biohit Oyj is a Finnish biotechnology company that operates internationally. Biohit’s mission is Innovating for Health – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the United Kingdom. Biohit’s series B share (BIOBV) is listed on Nasdaq OMX Helsinki in the Small Cap/Healthcare group. www.biohithealthcare.com